Asset profile
Ramucirumab
Monoclonal antibody
Approvedregulatory verdict
Evidence outlook
Approved: Non-Small Cell Lung Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
61 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Ramucirumab: this drug | Approved | Monoclonal antibody | VEGFR2 | ||
| Apatinib | Phase 3 | Small molecule | VEGFR2 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 | ||
| Brigatinib | Approved | Small molecule | ALK | ||
| Capmatinib | Approved | Small molecule | MET | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Ceritinib | Approved | Small molecule | ALK |
…and 46 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(29 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3)
December 2026 (3)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT03909334 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT03527108 · CT.gov ↗
What to watch
Phase 2Gastroesophageal AdenocarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06043427 · CT.gov ↗
What to watch
2027 (13)
February 2027 (1)
Phase 2Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8 …Recruiting
Est. primary completion 2027-02-01 · NCT04205968 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Neoplasms, Child, AdolescentRecruiting
Est. primary completion 2027-05 · NCT05999994 · CT.gov ↗
What to watch
June 2027 (4)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT04999761 · CT.gov ↗
What to watch
Phase 2Gastric Cancer (Diagnosis)Not yet recruiting
Est. primary completion 2027-06-01 · NCT07669740 · CT.gov ↗
What to watch
Phase 2Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8Recruiting
Est. primary completion 2027-06-30 · NCT05642572 · CT.gov ↗
What to watch
Phase 2Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma …Active not recruiting
Est. primary completion 2027-06-30 · NCT05980000 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-07-30 · NCT06448754 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer …Active not recruiting
Est. primary completion 2027-08-01 · NCT06251973 · CT.gov ↗
What to watch
Phase 2Gastric Cancer, GastroEsophageal Cancer, AdenocarcinomaActive not recruiting
Est. primary completion 2027-08-11 · NCT04069273 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Metastatic Gastro-esophageal AdenocarcinomaActive not recruiting
Est. primary completion 2027-09 · NCT06680622 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2/3Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma …Recruiting
Est. primary completion 2027-10-31 · NCT06203600 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1/2Metastatic Gastric Adenocarcinoma, Second Line, ChemotherapyRecruiting
Est. primary completion 2027-12-31 · NCT05927857 · CT.gov ↗
What to watch
Phase 2/3Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8Recruiting
Est. primary completion 2027-12-31 · NCT06616584 · CT.gov ↗
What to watch
2028 (5)
January 2028 (1)
Phase 1/2Solid CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT06771622 · CT.gov ↗
What to watch
May 2028 (3)
Phase 1/2Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal CancerRecruiting
Est. primary completion 2028-05-09 · NCT06445972 · CT.gov ↗
What to watch
Phase 1Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic AdenocarcinomaRecruiting
Est. primary completion 2028-05-31 · NCT05365581 · CT.gov ↗
What to watch
Phase 2Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8Recruiting
Est. primary completion 2028-05-31 · NCT06031688 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-08-17 · NCT06007937 · CT.gov ↗
What to watch
2029 (5)
January 2029 (1)
Phase 1Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Malignant Neoplasm in the PeritoneumRecruiting
Est. primary completion 2029-01-14 · NCT06675136 · CT.gov ↗
What to watch
February 2029 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-02-23 · NCT06996782 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-04-06 · NCT07098338 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Gastroesophageal AdenocarcinomaNot yet recruiting
Est. primary completion 2029-09 · NCT07763171 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Gastric Cancer Adenocarcinoma Metastatic, Gastric Adenocarcinoma and Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2029-12-31 · NCT06962137 · CT.gov ↗
What to watch
2030 (3)
January 2030 (1)
Phase 2HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric AdenocarcinomaRecruiting
Est. primary completion 2030-01 · NCT07546812 · CT.gov ↗
What to watch
April 2030 (1)
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2030-04-30 · NCT05719558 · CT.gov ↗
What to watch
September 2030 (1)
Phase 1Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 …Not yet recruiting
Est. primary completion 2030-09-09 · NCT07594548 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.